Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
TKI-CPK
National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
1 other identifier
observational
154
1 country
27
Brief Summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2010
Typical duration for all trials
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2010
CompletedFirst Submitted
Initial submission to the registry
November 24, 2010
CompletedFirst Posted
Study publicly available on registry
November 25, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 15, 2013
CompletedMarch 16, 2026
March 1, 2026
1 month
November 24, 2010
March 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the prevalence of the CPK increase
Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL
Within 3 days after a clinical exam
Secondary Outcomes (1)
Correlation myalgia/CPK increase
During the clinical exam
Study Arms (1)
Patient treated by TKI
Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
Interventions
Examination of the patient for myalgia, cramps, medical history and concomitant medication
CPK dosage during a blood sample realized at least one week after the begining of the treatment
Eligibility Criteria
Patients treated for a solid tumor by thyrosin kinase inhibitors
You may qualify if:
- Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
- Patient examined AND with a routine blood test planned
- Patient informed of procedure for the study who was not opposed to it
You may not qualify if:
- Patient treated for malignant hemopathy
- Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
- Patients with no routine blood laboratory tests planned
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (27)
Centre Paul Papin
Angers, 49000, France
Hôpital Jean Minjoz
Besançon, 25030, France
CHU Bordeaux
Bordeaux, 33076, France
Institut Bergonié
Bordeaux, 33076, France
Centre François Baclesse
Caen, 14076, France
Centre Jean Perrin
Clermont-Ferrand, 63011, France
Hôpital Henri Mondor - APHP
Créteil, 94010, France
Centre Oscar Lambret
Lille, 59020, France
CHU Limoges
Limoges, 87042, France
Hôpital Edouard Herriot
Lyon, 69003, France
Centre Léon Bérard
Lyon, 69008, France
Institut Paoli Calmettes
Marseille, 13273, France
Centre Val d'Aurelle
Montpellier, 34298, France
Centre Antoine Lacassagne
Nice, 06189, France
Hôpital Saint-Louis - APHP
Paris, 75010, France
Hôpital Cochin - APHP
Paris, 75014, France
Hôpital Tenon - APHP
Paris, 75020, France
Institut Curie
Paris, 75248, France
Institut Jean Godinot
Reims, 51056, France
CHU Robert Debré
Reims, 51092, France
Centre Eugène Marquis
Rennes, 35042, France
Centre Henri Becquerel
Rouen, 76000, France
Centre René Huguenin
Saint-Cloud, 92211, France
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42271, France
Institut Claudius Régaud
Toulouse, 31052, France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54511, France
Institut Gustave Roussy
Villejuif, 94805, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antoine ADENIS, MD, PhD
Centre Oscar Lambret
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2010
First Posted
November 25, 2010
Study Start
November 1, 2010
Primary Completion
December 1, 2010
Study Completion
January 15, 2013
Last Updated
March 16, 2026
Record last verified: 2026-03